Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Gespeichert in:
Autoren: | , , , , , , , , , , , , , |
---|---|
Format: | Artikel |
Sprog: | engelsk |
Udgivet: |
Philipps-Universität Marburg
2023
|
Fag: | |
Online adgang: | PDF-Volltext |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Vær først til at give en kommentarø!